Literature DB >> 24829004

Bias against the null hypothesis: scaring pregnant women about drugs in pregnancy.

Gideon Koren, Svetlana Madjunkova, Caroline Maltepe.   

Abstract

QUESTION: Since the thalidomide disaster, medicine is practised as if every drug is teratogenic, when in fact very few medications are. Pregnant women are often ready to refuse treatment even for life-threatening conditions owing to misinformation and misperceptions about fetal risks. How can I reassure my patients and prevent misinformation from affecting their treatment? ANSWER: Physicians must provide evidence-based counseling to their patients. For example, antihistamines for morning sickness have been proven safe in numerous studies, but are commonly the subject of media reports overstating the risks to the fetus. Family physicians and obstetricians must take an active role in preventing pregnant patients from being misinformed. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Year:  2014        PMID: 24829004      PMCID: PMC4020645     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  18 in total

1.  Reviewers' bias against the null hypothesis: the reproductive hazard of binge drinking.

Authors:  Gideon Koren; Andrea Fernandes
Journal:  J Popul Ther Clin Pharmacol       Date:  2010-07-20

Review 2.  Sources of bias in signals of pharmaceutical safety in pregnancy.

Authors:  Gideon Koren; Sheri Nickel
Journal:  Clin Invest Med       Date:  2010-12-01       Impact factor: 0.825

3.  Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis.

Authors:  A Seto; T Einarson; G Koren
Journal:  Am J Perinatol       Date:  1997-03       Impact factor: 1.862

4.  Bias against negative studies in newspaper reports of medical research.

Authors:  G Koren; N Klein
Journal:  JAMA       Date:  1991-10-02       Impact factor: 56.272

Review 5.  Bias against the null hypothesis in maternal-fetal pharmacology and toxicology.

Authors:  G Koren
Journal:  Clin Pharmacol Ther       Date:  1997-07       Impact factor: 6.875

6.  Bias against the null hypothesis: the reproductive hazards of cocaine.

Authors:  G Koren; K Graham; H Shear; T Einarson
Journal:  Lancet       Date:  1989-12-16       Impact factor: 79.321

7.  Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making.

Authors:  L Bonari; G Koren; T R Einarson; J D Jasper; A Taddio; A Einarson
Journal:  Arch Womens Ment Health       Date:  2005-06-17       Impact factor: 3.633

8.  Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies.

Authors:  P M McKeigue; S H Lamm; S Linn; J S Kutcher
Journal:  Teratology       Date:  1994-07

9.  Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester.

Authors:  G Koren; M Bologa; D Long; Y Feldman; N H Shear
Journal:  Am J Obstet Gynecol       Date:  1989-05       Impact factor: 8.661

10.  Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin.

Authors:  Irena Nulman; Joanne Rovet; Maru Barrera; Dafna Knittel-Keren; Brian M Feldman; Gideon Koren
Journal:  J Pediatr       Date:  2009-04-24       Impact factor: 4.406

View more
  4 in total

1.  Dissemination of Research Results: On the Path to Practice Change.

Authors:  David J Edwards
Journal:  Can J Hosp Pharm       Date:  2015 Nov-Dec

Review 2.  Insomnia during pregnancy: Diagnosis and Rational Interventions.

Authors:  Ali M Hashmi; Shashi K Bhatia; Subhash K Bhatia; Imran S Khawaja
Journal:  Pak J Med Sci       Date:  2016 Jul-Aug       Impact factor: 1.088

Review 3.  Preeclampsia - will orphan drug status facilitate innovative biological therapies?

Authors:  Sinuhe Hahn
Journal:  Front Surg       Date:  2015-02-26

4.  Medications and pregnancy: The role of community pharmacists - A descriptive study.

Authors:  Hoi Ying Leung; Bandana Saini; Helen E Ritchie
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.